title: Two-year results of intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion.
abstract: We investigated intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion in 20 patients. Mean central macular thickness at 3 days, 1, 3, 6, 12, 18, and 24 months postoperatively was different than baseline. Visual acuity did not change. Intravitreal triamcinolone injection significantly improves short-term anatomy, but recurrences and steroid-related complications were noted in the longer term.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Ankara University, Ankara, Turkey. fbatioglu@gmail.com
authors.forename: Figen
authors.initials: F
authors.lastname: Batioglu
authors.forename: Emin
authors.initials: E
authors.lastname: Ozmert
authors.forename: Elif
authors.initials: E
authors.lastname: Akmese
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012170:Retinal Vein Occlusion / Q000150:complications*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide